Get to Know Dr. Joel M. Baumgartner
Surgical oncologist Dr. Joel Baumgartner is acclaimed for his expertise in treating rare abdominal malignancies such as peritoneal mesothelioma, appendix cancer and peritoneal carcinomatosis.
His specialty involves the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, also known as HIPEC, a combination that has advanced mesothelioma treatment and extended survival for many patients.
Moores Cancer Center is one of the few facilities on the West Coast using the technologically advanced combination, attracting patients throughout California who are seeking mesothelioma treatment.
Baumgartner joined Moores in 2012 after his fellowship at the University of Pittsburgh School of Medicine and Mesothelioma Specialty Care Center, one of the highest-volume HIPEC facilities in the world. His move was the perfect fit.
HIPEC involves bathing the entire abdominal cavity with a heated, high-concentration chemotherapy solution for 90 minutes after surgery.
It is designed kill any microscopic tumor cells that evaded the surgeon. The solution is removed before the patient leaves the operating room.
In addition to mesothelioma, Baumgartner has expertise treating several abdominal cancers, particularly those involving the GI tract.
Specialties of Dr. Joel M. Baumgartner
- Peritoneal mesothelioma
- Cytoreductive surgery
- Clinical trials
- Basal cell carcinoma
- Squamous cell carcinoma
- Appendix cancer
Dr. Joel M. Baumgartner’s Experience and Medical Education
- Moores Cancer Center at UC San Diego Health
- UC San Diego School of Medicine (Assistant professor)
- Indiana University School of Medicine (M.D.)
- University of Colorado School of Medicine (Residency)
- University of Pittsburgh School of Medicine (Fellowship)
Award and Certifications
- Board certified in general surgery
- Society of Surgical Oncology (Member)
- American Society of Clinical Oncology (Member)
- American Association for Cancer Research (Associate member)
Publications of Dr. Joel M. Baumgartner
- Baumgartner, J.M. et al. (2018, June 14). Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. Annals of Surgical Oncology.
- Reghunathan, M. et al. (2017, December 27). Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC. Annals of Surgical Oncology.
- Kelly, K. et al. (2017, October 31). Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology.
- Marmor, R.A. et al. (2015, November 5). Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery. Annals of Surgical Oncology.
Thank you for your feedback. Would you like to speak with a Patient Advocate?